Clinical Guidelines for Inpatient Delirium Medication Review

Abstract

Delirium is an acute neuropsychiatric syndrome commonly encountered in hospitalized patients, with significant implications for morbidity, mortality, and healthcare resource utilization. Medication review is a fundamental component of delirium management, aiming to identify and modify pharmacological contributors. This evidence-based review synthesizes current clinical guidelines and recent research, providing physicians and healthcare professionals with a comprehensive approach to inpatient delirium, including epidemiology, pathophysiology, risk factors, clinical features, diagnosis, and best practices for medication review and management. The article highlights the importance of multidisciplinary collaboration, ongoing assessment, and emerging therapeutic strategies to optimize outcomes in this vulnerable patient population.

Introduction

Delirium is a complex and often under-recognized syndrome characterized by acute onset of fluctuating disturbances in attention, consciousness, and cognition. It is particularly prevalent among hospitalized elderly patients, critically ill individuals, and those with multiple comorbidities. Delirium is associated with increased length of hospital stay, long-term cognitive impairment, institutionalization, and mortality. The multifactorial etiology of delirium necessitates a systematic and multifaceted approach to diagnosis and management, with a central focus on medication review to identify and mitigate iatrogenic contributors. This review evaluates the latest clinical guidelines, evidence, and practical approaches for conducting an effective medication review in the management of inpatient delirium.

Epidemiology / Disease Burden

Delirium affects approximately 15-50% of hospitalized older adults, with higher rates observed in intensive care units, postoperative settings, and patients with pre-existing cognitive impairment. The incidence varies according to patient population, setting, and diagnostic criteria. Delirium increases the risk of in-hospital complications, prolonged recovery, persistent functional decline, and mortality. The economic burden is substantial, with delirium-related hospital costs exceeding billions annually. Early identification and targeted interventions, including systematic medication review, are essential to attenuate the clinical and economic impact of delirium.

Pathophysiology

The pathophysiology of delirium is multifactorial and incompletely understood, involving disturbances in neurotransmitter systems (notably acetylcholine deficiency and dopaminergic excess), neuroinflammation, oxidative stress, cerebral hypoperfusion, and aberrant stress responses. Medications with anticholinergic, sedative, or psychoactive properties can precipitate or exacerbate delirium by disrupting neurochemical balance and altering neuronal signaling. Polypharmacy and drug-drug interactions further compound these risks, highlighting the necessity of careful pharmacological evaluation in at-risk populations.

Risk Factors

Predisposing risk factors include advanced age, baseline cognitive impairment or dementia, sensory deficits, multiple comorbidities, dehydration, and immobility. Precipitating factors commonly encountered in the inpatient setting comprise acute illness, infection, metabolic disturbances, surgery, use of physical restraints, and exposure to high-risk medications. Drugs implicated in delirium include benzodiazepines, opioids, anticholinergics, corticosteroids, antihistamines, and certain antibiotics (e.g., fluoroquinolones). Systematic medication review is critical in identifying modifiable risk factors and preventing iatrogenic delirium.

Clinical Features

Delirium presents as an acute change in mental status, characterized by inattention, disorganized thinking, altered level of consciousness, and perceptual disturbances. The clinical course is often fluctuating, with periods of lucidity interspersed with confusion. Delirium can be classified as hyperactive, hypoactive, or mixed, with hypoactive forms frequently underdiagnosed due to subtlety of presentation. Associated features may include hallucinations, delusions, motor agitation, emotional lability, and disrupted sleep-wake cycles. Prompt recognition of these features is essential for initiation of appropriate management.

Diagnosis

Diagnosis of delirium is clinical, based on criteria from the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) or tools such as the Confusion Assessment Method (CAM). A thorough assessment should include history, physical examination, review of laboratory and imaging studies, and systematic medication review. Identifying and addressing reversible contributors is a cornerstone of delirium management. Medication review should specifically evaluate recent drug changes, high-risk agents, cumulative anticholinergic burden, and potential drug-drug or drug-disease interactions.

Treatment & Management

Management of delirium is multifaceted, focusing on identification and reversal of underlying causes, environmental modifications, and supportive care. Non-pharmacological strategies, such as orientation, sleep hygiene, early mobilization, and sensory optimization, are first-line interventions. Medication review is pivotal: unnecessary or high-risk drugs should be discontinued or substituted, and dosages adjusted as appropriate. Pharmacological treatment is reserved for severe agitation or distress that threatens patient or staff safety, with antipsychotics (haloperidol, atypical antipsychotics) used judiciously and for the shortest duration necessary. Benzodiazepines are generally avoided except in cases of alcohol or benzodiazepine withdrawal delirium. Regular reassessment and multidisciplinary collaboration are essential components of ongoing management.

Recent Advances / Emerging Therapies

Recent research emphasizes the role of comprehensive medication reconciliation, pharmacist-led interventions, and electronic health record (EHR) decision support systems in reducing delirium incidence. Tools such as the Anticholinergic Cognitive Burden (ACB) scale and Beers Criteria facilitate identification of high-risk medications. Novel approaches under investigation include dexmedetomidine for sedation in critically ill patients and non-invasive neurostimulation techniques. Ongoing studies aim to refine risk stratification, identify biomarkers, and develop targeted therapies that modulate neuroinflammation and neurotransmitter imbalances.

Guideline Recommendations

Current guidelines from organizations such as the National Institute for Health and Care Excellence (NICE), the American Geriatrics Society, and the Society of Critical Care Medicine advocate systematic medication review as a central component of delirium prevention and management. Recommendations include minimizing use of deliriogenic drugs, avoiding polypharmacy, careful titration of necessary medications, and prioritizing non-pharmacological interventions. Guidelines stress the importance of multidisciplinary teamwork, regular re-evaluation, and patient- and family-centered care. They also encourage ongoing education and training for healthcare professionals in delirium recognition and management.

Conclusion

Inpatient delirium remains a significant clinical challenge with far-reaching consequences for patients and healthcare systems. Medication review is a critical, evidence-based strategy for reducing the incidence and severity of delirium, requiring vigilance, interdisciplinary collaboration, and adherence to established clinical guidelines. Advances in risk assessment tools, decision support, and emerging therapies hold promise for further improving outcomes. Continued education and research are essential to optimize prevention, early detection, and tailored management of delirium in the inpatient setting.